ProfileGDS5678 / 1460539_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 7% 7% 7% 7% 7% 7% 6% 7% 7% 7% 7% 7% 7% 7% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.175317
GSM967853U87-EV human glioblastoma xenograft - Control 22.152747
GSM967854U87-EV human glioblastoma xenograft - Control 32.154977
GSM967855U87-EV human glioblastoma xenograft - Control 42.112037
GSM967856U87-EV human glioblastoma xenograft - Control 52.103237
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.18827
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.152286
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.126437
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.125747
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.140027
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.133877
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.123977
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.147737
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.139637